Evidence map›Paper›PMID 37227903›Full record

ArticleIEEE transactions on medical imaging2023

Ipsilateral Lesion Detection Refinement for Tomosynthesis.

Yinhao Ren, Xuan Liu, Jun Ge, Zisheng Liang, Xiaoming Xu, Lars J Grimm, Jonathan Go, Jeffrey R Marks, Joseph Y Lo

Abstract read
In one paragraph

Article in IEEE transactions on medical imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yinhao Ren
Xuan Liu
Jun Ge
Zisheng Liang
Xiaoming Xu
Lars J Grimm
Jonathan Go
Jeffrey R Marks
Joseph Y Lo

Funding

Breast Cancer Detection ConsortiumU01CA214183 · NCI · DUKE UNIVERSITY · PI MARKS, JEFFREY R., TANG, CHA-MEI · 2016 to 2021
$2.4M
NCI NIH HHS U01 CA214183
6 · The paper itself

Abstract

Computer-aided detection (CAD) frameworks for breast cancer screening have been researched for several decades. Early adoption of deep-learning models in CAD frameworks has shown greatly improved detection performance compared to traditional CAD on single-view images. Recently, studies have improved performance by merging information from multiple views within each screening exam. Clinically, the integration of lesion correspondence during screening is a complicated decision process that depends on the correct execution of several referencing steps. However, most multi-view CAD frameworks are deep-learning-based black-box techniques. Fully end-to-end designs make it very difficult to analyze model behaviors and fine-tune performance. More importantly, the black-box nature of the techniques discourages clinical adoption due to the lack of explicit reasoning for each multi-view referencing step. Therefore, there is a need for a multi-view detection framework that can not only detect cancers accurately but also provide step-by-step, multi-view reasoning. In this work, we present Ipsilateral-Matching-Refinement Networks (IMR-Net) for digital breast tomosynthesis (DBT) lesion detection across multiple views. Our proposed framework adaptively refines the single-view detection scores based on explicit ipsilateral lesion matching. IMR-Net is built on a robust, single-view detection CAD pipeline with a commercial development DBT dataset of 24675 DBT volumetric views from 8034 exams. Performance is measured using location-based, case-level receiver operating characteristic (ROC) and case-level free-response ROC (FROC) analysis.

Indexed as

Breast NeoplasmsEarly Detection of CancerFemaleHumansMammographyRadiographic Image Interpretation, Computer-AssistedROC Curve

Identifiers

PMID37227903
PMCPMC11033619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.